Replies to post #50635 on Genta, Inc (fka GNTAQ)

[nutriman24]

ASCO 2011 Schedule for GNTA

Survival in a Phase 3, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH) (AGENDA). Abstract #8531. Poster Session: Monday, June 6, 2011 8:00 AM-12:30 PM; Discussion Session 11:30 AM-12:30 PM.

Dose-ranging study of tesetaxel, a novel oral taxane, administered as second-line therapy at a flat dose to patients with advanced gastric cancer. Abstract #4110. General Poster Session: Saturday, June 4, 2011 8:00 AM–12:00 PM

Abraxane, temozolomide and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). Abstract #8545. General Poster Session: Sunday, June 5, 2011 8:00 AM–12:00 PM

Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer. Abstract #TPS123. Trials in Progress Poster Session: Monday, June 6, 2011 8:00 AM-12:00 PM

Clinical evaluation of food effects on pharmacokinetics of the novel oral taxane, tesetaxel. Abstract #e13059. Electronic publishing.

About Genta